Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Understanding the Continuum between High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia.

International journal of molecular sciences - 6 Mar 2023

Zavras Phaedon D, Sinanidis Ilias, Tsakiroglou Panagiotis, Karantanos Theodoros

Abstract excerpt

Myelodysplastic syndrome (MDS) is a clonal hematopoietic neoplasm characterized by bone marrow dysplasia, failure of hematopoiesis and variable risk of progression to acute myeloid leukemia (AML). Recent large-scale studies have demonstrated that distinct molecular abnormalities detected at earlier stages of MDS alter disease biology and predict progression to AML. Consistently, various studies analyzing these...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chromosome Aberrations
Share to Leukemia, Myeloid, Acute

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Mutation

Share to Myelodysplastic Syndromes

Source

Open in PubMed Open full text

Identifiers

PMID: 36902450
DOI: 10.3390/ijms24055018
PMCID: PMC10002503

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Understanding the Continuum between High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia.PMID 36902450Read ↗

Myelodysplastic syndromes: recent advancements in risk stratification and unmet therapeutic challenges.Semantic proximity Read ↗

Myelodysplastic SyndromesSemantic proximity Read ↗

Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.Semantic proximity Read ↗

Definitions, Biology, and Current Therapeutic Landscape of Myelodysplastic/Myeloproliferative NeoplasmsSemantic proximity Read ↗

Navigating the contested borders between myelodysplastic syndrome and acute myeloid leukemiaSemantic proximity Read ↗

Myelodysplastic and myeloproliferative neoplasms: updates on the overlap syndromes.Semantic proximity Read ↗

Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a focused review.Semantic proximity Read ↗

Myelodysplastic syndromes: Updates on Genomic Landscape, Molecular Subtypes, & Targeted Therapies.Semantic proximity Read ↗

The genetics of myelodysplastic syndromes and the opportunities for tailored treatmentsSemantic proximity Read ↗

[New insights into the nature and classification of myelodysplastic neopmasm].Semantic proximity Read ↗

Clinico-genetic and prognostic analyses of 716 patients with primary myelodysplastic syndrome and myelodysplastic syndrome/acute myeloid leukemia based on the 2022 International Consensus Classification.Semantic proximity Read ↗

The myelodysplastic syndromes: diagnosis, molecular biology and risk assessment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.